Dialuminum tetramagnesium carbonate dodecahydroxide

Endpoint summary

Description of key information

Read across from Alcamizer 5 (422-150-1) and Aluminium-magnesium-zinc-carbonate-hydroxide (EC 423-570-6).
Alcamizer 5: 
Acute oral study (EEC-Directive 92/69 B.1, according to GLP principles): Alcamizer 5 has been tested in a gavage study. The LD50 was established to be > 2000 mg/kg.
Acute inhalation study (OECD 403 according to GLP principles):  The LC50 was established to be > 5.16 mg/l (4 h exposure).	
Dermal acute toxicity (EEC-Directive 92/69 B.3, according to GLP principles): 
Alcamizer5 has been tested in a 24-hours, semi-occlusive study exposing 5 males and 4 females Wistar Crl: (WI)BR rat to 2000 mg/kg bw. 
No mortality occurred and no clinical signs were observed. The LD50 was established to be > 2000 mg/kg bw. 
Aluminium-magnesium-zinc-carbonate-hydroxide:
Acute oral study (EEC-Directive 92/69 B.1, according to GLP principles): Aluminium-magnesium-zinc-carbonate-hydroxide-(hydrate) has been 
tested in a gavage study exposing 5 males and 5 females wistar rat to 2000 mg/kg bw. No mortality occurred and no clinical signs were observed. The LD50 was established to be > 2000 mg/kg bw.
Acute inhalation study (OECD 403 according to GLP principles):
Aluminium-magnesium-zinc-carbonate-hydroxide-(hydrate) has been tested in a nose only study exposing for 4-hours 5 males and 5 females 
wistar rat to a concentration of 5.17 mg/l. No mortality occurred. Slight visually decreased breathing rate in all animals during the first two hours, 
aggravating to moderate decreased breathing rate in the last two hours. Findings at necropsy were limited to discouraging of the lungs seen in three 
animals. The LC50 was established to be > 5.17 mg/l.
Supporting study:
single dose toxicity study: [carbonato(2-)]hexadecahydroxybis(aluminium)hexamagnesium caused no mortality when administered orally, subcutaneously or intraperitoneally, to male mice up to a dose level of 10 gram/kg. 

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

Study performed in accordance with OECD guideline and in compliance with GLP guidelines. As the study is performed with a substance analogue, in accordance with REACH guidance the maximum reliability for read-across data is 2. Read-across is justified because of the similar chemical nature of the target substance compared to the analogues. The read-across rationale can be found in the analogue approach document attached in Section 13.

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LC50

Value:

5.16 mg/m³ air

Quality of whole database:

Study performed in accordance with OECD guideline and in compliance with GLP guidelines. As the study is performed with a substance analogue, in accordance with REACH guidance the maximum reliability for read-across data is 2. Read-across is justified because of the similar chemical nature of the target substance compared to the analogues. The read-across rationale can be found in the analogue approach document attached in Section 13.

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

Study performed in accordance with OECD guideline and in compliance with GLP guidelines. As the study is performed with a substance analogue, in accordance with REACH guidance the maximum reliability for read-across data is 2. Read-across is justified because of the similar chemical nature of the target substance compared to the analogues. The read-across rationale can be found in the analogue approach document attached in Section 13.

Additional information

Based on studies performed on Aluminium-magnesium-zinc-carbonate-hydroxide as well as on Alcamizer 5 and a supporting study on the substance, it can be concluded that the substance Aluminium magnesium carbonate hydroxide

is not considered toxic via dermal, oral or inhalation route, in acute toxicity tests.

 

EC #	423-570-6	422-150-1	Not yet assigned
Name	P93	Alcamizer 5	Aluminium magnesium carbonate hydroxide
Acute oral (LD50) [mg/kg bw]	> 2000	> 2000	read-across: > 2000
Acute dermal (LD50) [mg/kg bw]	no data	> 2000	read-across: > 2000
Acute inhalation [mg/L]	> 5.17	> 5.16	read-across: > 5.16

Justification for selection of acute toxicity – oral endpoint
The analogue P93 show minimal acute toxicity resulting in oral LD50 >2000 mg/kg bw.

Justification for selection of acute toxicity – inhalation endpoint
The analogue Alcamizer 5 show minimal acute toxicity resulting in LC50 >5.16 mg/L air.

Justification for selection of acute toxicity – dermal endpoint
The analogue Alcamizer 5 show minimal acute toxicity resulting in dermal LD50 >2000 mg/kg bw.

Justification for classification or non-classification

Based on the results of the studies performed with substance analogues, the substance Aluminium magnesium carbonate hydroxide

does not have to be classified for acute toxicity according to Regulation (EC) No 1272/2008 .